75 YEARS:

MACEDONIAN SUCCESS

STORY

Powered by SAP

MHRA GMP Compliance Certified

JAZMP GMP Compliance Certified

RNMA PIC/s GMP Compliance Certified

JFDA Approved

HACCP Certified

EU, JAS, USDA-NOP Organic Production Certified

ISO 9001, ISO 14001, ISO 13485

CE Certified

FAIRWILD Certified

Established: 15 August 1936

Main Activities: Pharmaceuticals, Chemicals, Cosmetics, Botanicals

No. of employees: 1,050 in HQ and + 300 abroad

No. of shareholders: > 5,500

Alkaloid in General

Sales network comprising 12

subsidiaries and 3 Rep. Offices

headed from the base in Macedonia.

Alkaloid in General

In the past 13 years, the Company underwent and investment cycle

worth nearly EUR 100 mil, allocated mainly in the pharmaceuticals

segment:

Investments

• Factories for solid dosage forms and for semi-synthetic

cephalosporines (cGMP)

• Warehouses, storage facilities and their infrastructure

• Microbiological and Chemical Laboratories

• IT Segment; Implementation of SAP/ERP; DMS; CRM etc.

• New Institute for Development and Quality Control

• New production facility in Belgrade, Republic of Serbia

• Production equipment (continuous)

Investments

Pharmaceutical industry: Dynamic state of affairs

All these investments led to obtaining various GMP certificates for the

international markets (British Medicines and Healthcare products

Regulatory Agency – MHRA; Slovenian Agency for Drugs and

Medicinal Products; Romanian Ministry of Health; Jordan Food and

Drugs Administration, Pre-US FDA Approval etc.) thus giving the

company the right to market its products worldwide thereby increasing

its level of competence.

Sales | Geographical spread

Macedonia 41%

Export 59%

Sales | Structure of Export Sales

Former YU: 41%

EU: 8%

Russia and CIS: 7%

USA: 1%

Others : 2%

Leading Brands

• Launched in 1957 with more than 10 bil. tablets sold so far, present

in the markets of 27 countries

• Superbrand for Serbia (2007), Bosnia & Herzegovina (2008) and

Macedonia (2009)

• 4 New extensions since year 2005:

Consumers do not communicate with anonymous products,

but they built a relationship with a brand, indentifying therein their own

values and beliefs. Investment in brands, is one of our priorities.

The golden superbrand: CAFFETIN

Leading Brands

• Synonym for quality, confidence and tradition

• First introduced in 1977 as babycare collection containing only 5

products. Today, the portfolio contains over 30 products with more than

100 million pieces sold.

• 60% market share in Macedonia. Well positioned in other SEE markets.

• Superbrand for Bosnia & Herzegovina (2008), Macedonia and Croatia

(in 2009)

Standings and prospects

All 14 subsidiaries with over 300 employments abroad are in the

function of enhancing the export orientation of the Company. Alkaloid

is making strong investment efforts for building competent marketing

and sales teams.

6th Pharmaceutical Industry in South Eastern Europe.

Alkaloid’s strategic policy for growth is also aimed at acquiring

pharmaceutical companies outside of Macedonia. First production

facility in Belgrade was opened in 2010.

Alkaloid’s products are present in almost 30 markets worldwide.

Standings and prospects

Alkaloid is open for all types of cooperation and synergies.

Various types of alliances: license production agreements,

contract manufacturing production, distributions for multinationals

etc.

Present pharmaceuticals portfolio: 144 pharmaceutical products

with over 340 forms. One cannot excel in all.

Specialization in cephalosporins (one of the few manufacturers),

cardio preparations and CNS drugs.

Focus on pharmaceuticals and correlated activities.

Standings and prospects

The success in Alkaloid’s operations is mostly due to the quality of

the products, the well-trained personnel working in the company,

the very brand Alkaloid and the individual brands.

Appropriate know-how along with well-thought flexible and vigilant

strategy for individual market(s) approach is also an important

condition.

Sustainable products, team work and proactive marketing concept

stands for added value to our performance.

Alkaloid: 3rd world country manufacturer?!

With every new market conquered with our own efforts, the

success of the company becomes a success of our country.

A Partner of Choice

F. Hoffmann - La Roche Sanofi Aventis Italfarmaco Valeant (Pharmaswiss) Talecris Pfizer Nycomed Novartis Mundifarma B. Braun GSK Actavis

Sandoz Shire

• More than 20 products in the license program

• Over 150 products on consignment and distribution stock (distributed

through Alkaloid Cons Ltd.)

A Partner of Choice

Botanicals Segment: (EU, JAS, USDA-NOP Organic Production Certified /

FAIRWILD Certified)

2005: Production agreement with the US company Aveda (Member of Estèe

Lauder Group) for production of Comforting tea.

2011: New production agreement with Arbonne International from USA for

detox tea intended for the markets of Canada, USA, UK and the Pacific

region.

Medicine: Certificate for CE compliance by KEMA Quality BV for

haemodialysis solutions and X-ray films).

1981: Established partnership with FUJI Corporation, Japan for X-ray films.

2009: Alkaloid entered into cooperation agreement with the Japaneese

NIPRO for haemodialysis solution.

1977: Cooperation with Merck from Germany for production of argentum

salts.

SALES (in 000 EUR)

0

20000

40000

60000

80000

100000

120000

2006 2007 2008 2009 2010 2011

57

.79

7

69

.29

3

77

.21

6

89

.17

4

96

.46

9

10

8.0

00

2006-2010: Consolidated

2011: Projected

Investor Information

2006 2007 2008 2009 2010

Jan-Sep

2011

No. of shares 166,647 215,729 135,966 90,556 72,709 63,689

in EUR mil. 12.831 33.144 16.173 6.483 4.950 4.466

Trade with Alkaloid’s shares on the MSE

Current market capitalization:

~ 100,000,000 - 115,000,000 EUR

Alkaloid’s shares stand for one of the most liquid and most traded

shares on the first official market on the Macedonian stock

exchange.

According to MSE indicators:

1 EUR = 61.5 MKD

Future Focus

Further development of the pharmaceutical segment, satisfying the needs

of the stakeholders and contributing to the social needs of the nation.

Maintain the trend of growth and development via:

• Entry into new markets

• Increase of production and export volume

• Expanding the product portfolio

• Licensing foreign companies

• Acquisition of companies in pharmaceutical industry

• Building higher brand awareness

Besides being recognized as stabile and reliable company, acknowledged

partner with years of international experience, open for new partnerships

and all forms of cooperation, Alkaloid shall strive to earn the title: A

STABILE PARTNER FOR THE FUTURE